MDR-001, an AI-enabled Oral GLP-1 Receptor Agonist: Efficacy and Safety in Chinese Adults With Overweight or Obesity
MindRank
AI Drug Developer
American Diabetes Association
2026 Scientific Sessions
June 5–8, 2026 (local time),The 86th Scientific Sessions of the American Diabetes Association (ADA) will be grandly held in New Orleans, USA.As the authoritative academic bellwether in the global field of diabetes, this year’s annual meeting will bring together more than 12,000 top clinical experts, research scholars, and frontline healthcare professionals from around the world, creating a high-level, specialized international platform for sharing cutting-edge diagnostic and therapeutic advances, fostering breakthroughs in technological innovation, and facilitating in-depth cross-border academic collaboration.
MindRank’s independently developedLatest Clinical Research Findings on AI-Assisted Design of the Oral Small-Molecule GLP-1 Receptor Agonist MDR-001"Successfully selected for this conference, it will showcase its latest breakthrough data in the field of weight loss to global scholars."
Specific information is as follows:
Title
MDR-001, an AI-enabled Oral GLP-1 Receptor Agonist: Efficacy and Safety in Chinese Adults With Overweight or Obesity
AI-Enabled Oral GLP-1 Receptor Agonist MDR-001: A Study on Efficacy and Safety in Chinese Adults with Overweight or Obesity
Presenting Author
Leili Gao, Doctor
Professor Gao Leili, Peking University People's Hospital
Session Title
23-B Obesity-Human
Poster Number
2620-P
Session Time
June 8, 2026, 12:30 PM — 1:30 PM
（New Orleans, Louisiana）
Location
Poster Hall (Halls D-E)
MDR-001 is an innovative oral small-molecule GLP-1 receptor agonist developed by MindRank using its proprietary AI-assisted design platform. Leveraging the AI platform Molecule DanceTMGuided by precise structure-based design, MDR-001 specifically activates the GLP-1R/stimulatory G protein signaling pathway, efficiently promoting insulin secretion and appetite suppression; it differentially regulates β-arrestin2 recruitment, reducing the risk of receptor desensitization.While exerting its weight-loss effects, it can promote the synergistic repair of pancreatic β-cell function, demonstrating significant mechanistic differentiation and potential clinical advantages.
More detailed research data will be officially disclosed during the conference. Stay tuned!
About MindRank
MindRank is a globally leading AI-for-drug-discovery technology innovation company, dedicated to empowering new drug development through machine learning, reinforcement learning, and first-principles calculations. Leveraging its proprietary one-stop AI platform that deeply integrates biology, structural biology, chemistry, and medicine, MindRank pushes the boundaries of pharmaceutical technologies, ensuring more diseases become treatable and more lives regain health.
For more information, please visit the website:
www.mindrank.ai
Collaboration: bd@mindrank.ai
Others: info@mindrank.ai
END
